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Background. Acute coronary syndrome (ACS) can complicate acute ischemic stroke, causing significantmorbidity andmortality. To
date, literatures that describe poststroke acute coronary syndrome and itsmorbidity andmortality burden are lacking.Methods.This
is a single center, retrospective study where clinical characteristics, cardiac evaluation, and management of patients with suspected
poststroke ACS were compared and analyzed for their association with inpatient mortality and 1-year all-cause mortality. Results.
Of the 82 patients, 32% had chest pain and 88% had ischemic ECG changes; mean peak troponin level was 18, and mean ejection
fraction was 40%.The medical management group had older individuals (73 versus 67 years, 𝑝 < 0.05), lower mean peak troponin
levels (12 versus 49, 𝑝 < 0.05), and lower mean length of stay (12 versus 25 days, 𝑝 < 0.05) compared to those who underwent
stent or CABG. Troponin levels were significantly associated with 1-year all-cause mortality. Conclusion. Age and troponin level
appear to play a role in the current clinical decision making for patient with suspected poststroke ACS. Troponin level appears to
significantly correlate with 1-year all-cause mortality. In the management of poststroke acute coronary syndrome, optimal medical
therapy had similar inpatient and all-cause mortality compared to PCI and/or CABG.
1. Introduction
Acute coronary syndrome can complicate acute ischemic
stroke. In the Randomized Trial of Tirilazad Mesylate in
Patients with Acute Stroke (RANTTAS trial), cardiac ische-
mia was found to occur in 6% of patients, with 1% being life-
threatening [1]. A study by Chin found that acute coronary
syndrome occurred in 12.7% of patients within 3 days of an
acute ischemic stroke [2]. Cardiac abnormalities also were
found to be the most common cause of death after stroke.
Six percent of unexpected deaths in these cases occurred in
the first month [3]. Even 3.5 years after a stroke, patients were
still found to have an annual 2% risk of myocardial infarction
[4].
Neurologic events are known to cause myocardial injury
and dysfunction. Cardiac injury after an acute stroke has been
shown to occur even in the absence of underlying coronary
artery disease [5]. There is a strong association between
cerebrovascular disease and coronary artery disease [4]: Both
stroke and coronary artery disease have the same risk factors
[6] and there is high prevalence of cardiac disease among
stroke patients [7]. However, the literature is scant, not only
in describing patients with ischemic brain infarct and acute
coronary syndrome, but also in regard to their evaluation
Hindawi
Cardiology Research and Practice
Volume 2017, Article ID 3762149, 6 pages
https://doi.org/10.1155/2017/3762149
2 Cardiology Research and Practice
and medical management. Current practice for myocardial
infarction after a stroke is a full cardiacwork-up and coronary
angiography is needed to rule out significant coronary artery
disease [8, 9].
Given the lack of guidelines and literature for poststroke
ACS patients, the objectives of this study were to describe
the demographics and comorbidities of patients with post-
stroke acute coronary syndrome, including their presenting
symptom, peak troponin level, presence of ischemic elec-
trocardiogram (ECG) changes, 2D-echocardiograms, and
cardiac catheterization results. We compared the clinical
characteristics and cardiac evaluation of patients who were
medically managed and those who underwent any invasive
intervention with percutaneous coronary intervention (PCI)
or coronary artery bypass graft surgery (CABG). We sought
to determine if there is a difference in inpatient mortality and
1-year all-cause mortality among these patients.
2. Methodology
This is a retrospective cohort study on adult patients who
were admitted for acute ischemic stroke at Albert Einstein
Medical Center from January 2003 to December 31, 2013,
and developed acute coronary syndrome within 72 hours
after ischemic stroke. Acute coronary syndrome referred to
patients who fulfilled the third universal definition criteria of
elevated cardiac biomarkers of at least one value above the
99th percentile upper reference limit and one of the following:
symptoms of ischemia, development of pathologicQwaves in
the electrocardiogram, new or presumed new significant ST-
segment-T-wave (ST-T) changes or new left bundle branch
block (LBBB), and imaging evidence of new loss of viable
myocardium or a new regional wall motion abnormality.
We excluded the patients with age < 18 years, patients with
intracerebral hemorrhage, subarachnoid hemorrhage, hem-
orrhagic contusions, epidural hemorrhage, subdural hemor-
rhage, and other brain lesions, and patients with end stage
renal disease on hemodialysis.
Baseline demographic data (age, gender, race, and body
mass index) and comorbidities such as preexisting coronary
artery disease, hypertension, hyperlipidemia, diabetes melli-
tus, chronic kidney disease, congestive heart failure (systolic
and/or diastolic heart failure), coronary artery disease equiv-
alents (i.e., peripheral artery disease and carotid artery dis-
ease), and smoking history were collected. Results of cardiac
evaluation such as peak troponin level, ECG changes, 2D-
transthoracic echocardiograms, and cardiac catheterization
were also obtained. The primary outcomes of the study were
inpatient mortality and 1-year all-cause mortality from the
time of the acute ischemic stroke. The mortality information
was acquired using social security database index (SSDI).
For data analysis, categorical data were presented as num-
bers and percentages and continuous data asmean± standard
deviation. The demographic characteristics, comorbidities,
and cardiac evaluation results of those who were medically
managed versus those who underwent cardiac catheteriza-
tion and subsequent stent placement or CABG were com-
pared using Student’s 𝑡-test to test for differences between
independent continuous variables and the chi-square test
Table 1: Demographic data of patients with poststroke acute coro-
nary syndrome.
Total (%)
𝑁 (%) 82
Mean age (years) 72 ± 12.5
Gender
Female 43 (52%)
Male 39 (48%)
Race
Caucasian 24 (30%)
African American 51 (62%)
Hispanic 5 (6%)
Asian 2 (2%)
Comorbidities
Coronary artery disease 36 (44%)
Body mass index > 30 22 (33%)
Hypertension 79 (96%)
Hyperlipidemia 37 (45%)
Diabetes mellitus 46 (56%)
Chronic kidney disease 24 (29%)
Congestive heart failure 38 (46%)
Coronary artery disease equivalents 15 (18%)
Smoker 20 (24%)
to test for differences between categorical variables. For
continuous data that are not normally distributed, a non-
parametric test will be used. For example, a rank-sum test
(Kruskal-Wallis test) will be used instead of 𝑡-test. In a 2 ×
2 table, if one of the cells contains an expected value of
less than 5, Fisher exact test will be used instead of chi-
square test. To measure the association between an outcome
variable (inpatient mortality and 1-year all-cause mortality)
and selected exposure variable, such as peak troponin level,
ischemic changes in ECG, and intervention, the relative risk
will be computed. The chi-square or Fisher exact test will be
used to determine the significance of the association.
3. Results
Among adult patients admitted to Albert Einstein Medical
Center from 2003 to 2013, there were 82 patients who had an
acute coronary syndrome after an acute ischemic stroke. The
mean age was 72 years; 52% were female. Sixty-two percent
of the patients in the study were African American, 30%were
Caucasian, 6% were Hispanic, and 2% were Asian (Table 1).
Most of the patients in the study were found to have
hypertension (96%). The next most common comorbidities
were diabetes mellitus (56%), hyperlipidemia (45%), known
coronary artery disease (44%), and congestive heart failure
(46%). One-third of the population had a body mass index
above 30 or chronic kidney disease. Around 20% were
smokers or had coronary artery disease equivalents (Table 1).
Surprisingly, among patients who had acute coronary
syndrome after an acute ischemic stroke, only 32% com-
plained of chest pain. Other criteria for acute coronary
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Table 2: Clinical data and management of patients with poststroke
acute coronary syndrome.
Total (%)
Chest pain 26 (32%)
Mean peak troponin level 18 ± 33
ECG: presence of ischemic ECG changes 72 (88%)
Echo
Mean EF% 40 ± 20
Presence of wall motion abnormalities 35 (43%)
Corresponding to ischemic ECG changes 72 (88%)
Not corresponding to ischemic ECG changes 10 (12%)
Cardiac catheterization
Did not undergo cardiac catheterization 55 (67%)
Underwent cardiac catheterization 27 (33%)
Cardiac catheterization results:
No significant coronary artery disease 4 (15%)
1-vessel disease 7 (26%)
2-vessel disease 4 (15%)
3-vessel disease 12 (44%)
Management
Medical management 69 (84%)
Stent or CABG 13 (16%)
Mean length of stay (days) 14 ± 13
syndrome occurred more frequently. Ischemic ECG changes
(i.e., new T-wave inversions, new Q waves, new LBBB, ST-
segment elevations, and ST-segment depressions) were found
88% of the time. The most common ischemic ECG change
was new T-wave inversion (78%). Mean peak troponin level
was 18. Wall motion abnormalities on 2D-echocardiograms
occurred in 43% of the patients with 88% in coronary artery
territories corresponding to the ischemic ECG changes. The
mean ejection fraction of the patients in the study was 40%
(Table 2).
Although the patients had acute coronary syndromes,
67% did not undergo cardiac catheterization and were man-
aged conservatively. Of the 33% who underwent cardiac
catheterization, 15% had no significant coronary artery dis-
ease, 26% had 1-vessel disease, 15% had 2-vessel disease, and
44% had 3-vessel disease. Overall, out of the 82 patients, only
16% underwent placement of stents or CABG.The remaining
84% were managed medically. Medical management was
in accordance with the guideline-directed medical therapy
for acute coronary syndromes and congestive heart failure
by the American College of Cardiology/American Heart
Association guidelines that include aspirin, clopidogrel, and
beta-blockers. For those with reduced ejection fraction, ACE
inhibitors, beta-blockers, hydralazine/nitrates, and so on
(depending on patient’s clinical status) were given.The mean
length of stay was 14 days (Table 2).
The medical management group was significantly older
(73 versus 67 years, 𝑝 < 0.05) and had a significantly lower
length of stay (12 versus 25 days, 𝑝 < 0.05) (Table 3). In terms
of comorbidities, the two groups were the same (Table 3). As
for markers of cardiac injury, the mean peak troponin level
for the medical management group was 12 compared to the
intervention group, which was 49. There was no significant
difference between the two when it comes to presence
of ischemic ECG changes and 2D-echo results (i.e., mean
ejection fraction and presence of wall motion abnormality)
(Table 4).
There was a trend towards inpatient mortality among
patients who were managedmedically compared to the inter-
vention group, although this was not significantly different
(32% versus 23%, 𝑝 > 0.05). The 1-year all-cause mortality,
however, was similar (52% versus 54%, 𝑝 > 0.05) (Tables 5(a)
and 5(b)).
4. Discussion
The main findings of this study show that age and troponin
level appear to play a role in the current clinical decision
making for patientswith suspected poststrokeACS. Troponin
level appears to significantly correlate with 1-year all-cause
mortality. In the management of poststroke acute coronary
syndrome, optimalmedical therapy had similar inpatient and
all-causemortality compared to PCI and/orCABG.Although
there was a trend towards inpatient mortality among patients
who were managed medically compared to the intervention
group, it was not found to be statistically significant (𝑝 >
0.05) (Tables 5(a) and 5(b)). The 1-year all-cause mortality
rates were also found to be similar between the two groups,
with 52% for the medical management groups and 54% for
the intervention group.
Most patients who had acute coronary syndrome after
an acute ischemic stroke did not have any symptoms that
pertain to the ACS. Only around 30% had chest pain. This
may be explained by language or cognitive impairments that
occur in the setting of acute ischemic stroke. Alternatively,
it is possible that many of the cases presented as a silent
myocardial infarction.The patients’ troponin levels, however,
reflect a significant amount of cardiac injury, being remark-
ably elevated to amean of 18.This emphasizes the importance
of cardiac evaluation in acute ischemic stroke patients, even
without obvious typical symptoms.
In a study by Chalela et al., troponin elevation was
found to occur in 6% of patients with acute ischemic stroke.
In another study, 53.4% of the patients admitted for acute
ischemic stroke have elevated troponin, although only 6.6%
met the criteria for acute coronary syndrome [10]. Interest-
ingly, the study also showed that elevated troponin levels
correlated with older age, history of coronary artery disease,
congestive heart failure, diabetes mellitus, and renal disease
[11]. An elevated troponin level was also associated with
severity of stroke [10], poor outcomes, and death [12]. Tro-
ponin levels were associated with predicting a modified
Rankin score, a measure to determine the degree of disability
in doing activities of daily living, of 5 (bedridden) or 6 (death)
[12]. Furthermore, a study by Scheitz et al. showed that an
elevated troponin level was an independent predictor of poor
outcome and in-hospital mortality [13]. In our study, the
troponin levels revealed being significantly related to 1-year
all-causemortality, with 15 out of the 82 patients dying within
1 year of the ischemic stroke (Tables 5(a) and 5(b)). In contrast
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Table 3: Patient characteristics of those who underwent medical management versus intervention (stent or CABG).
Medical management Stent or CABG 𝑝 value
𝑁 (%) 69 (84%) 13 (16%)
Mean age (years) 73 ± 13 67 ± 7 𝑝 = 0.02
Gender
Female 38 (88%) 5 (12%)
𝑝 = 0.21
Male 31 (80%) 8 (20%)
Race 𝑝 = 0.6
Caucasian 20 (83%) 4 (17%)
African American 42 (82%) 9 (18%)
Hispanic 5 (100%) 0 (0%)
Asian 2 (100%) 0 (0%)
Mean length of stay (days) 12 ± 10 25 ± 21 𝑝 = 0.005
Comorbidities
Coronary artery disease 29 (80%) 7 (20%) 𝑝 = 0.3
Body mass index > 30 17 (77%) 5 (23%) 𝑝 = 0.44
Hypertension 66 (83%) 13 (17%) 𝑝 = 0.5
Hyperlipidemia 32 (86%) 5 (14%) 𝑝 = 0.41
Diabetes mellitus 39 (85%) 7 (15%) 𝑝 = 0.5
Chronic kidney disease 20 (83%) 4 (17%) 𝑝 = 0.5
Congestive heart failure 30 (79%) 8 (21%) 𝑝 = 0.18
Coronary artery disease equivalents 12 (80%) 3 (20%) 𝑝 = 0.8
Smoker 15 (75%) 5 (25%) 𝑝 = 0.17
Table 4: Cardiac evaluation results of patients who underwent medical management versus intervention (stent or CABG).
Medical management Stent + CABG Stat test 𝑝 value
Mean peak troponin 12 ± 17 49 ± 64 Kruskal-Wallis 0.005
Ischemic ECG changes
With 62 10 Fisher exact 0.19
Without 7 3
2D-echocardiogram
Mean ejection 40 ± 18 38 ± 17 𝑡-test 0.64
Wall motion abnormality
Present 39 8 Chi-square 0.11
Absent 30 5
to Scheitz’s study, our data did not show that troponin level is
associated with inpatient mortality. However, because results
across multiple studies have been different, it remains to be
determined if troponin level correlates only with the severity
of stroke or whether it is an independent predictor of death
[14].
A clinical review by Davis et al. showed that the most
frequent ECG abnormalities in acute stroke patients were
prolonged QT interval and ST-T changes [15]. In a study
by Dogan et al., on the other hand, 65% of patients had
ischemia-like ECG changeswith themost common one being
T-wave inversion [16]. In our study, presence of ischemic ECG
changes was found in 88% of the patients and similarly to
Dogan’s study the most common abnormality was T-wave
inversion (89%). Although Dogan’s study showed that ST-
segment changes were an independent predictor of mortal-
ity, a large scale study by Goldstein showed that ischemic
ECG changes were not associated with mortality in stroke
patients [17].Our studywas consistentwithGoldstein’s results
showing that ischemic ECG changes did not correlate with
inpatient mortality or 1-year all-cause mortality (Tables 5(a)
and 5(b)).
Our study revealed that patients who had acute coronary
syndrome in the setting of acute ischemic stroke had low
ejection fraction and wall motion abnormalities. The mean
EF of our patients is 40, which is close to the results of a study
by Bulsara et al., where the mean EF of the patients was 33%.
In Bulsara’s study, the findings in the ECGs did not match the
wall motion abnormalities in the 2D-echocardiograms [18].
Our study, however, showed that wall motion abnormalities
correlated with the ischemic changes found in the ECG
(Table 2). In a study done with subarachnoid hemorrhage
patients, wall hypokinesis was present in the first 2 days and
there was partial or complete resolution of the wall motion
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Table 5: (a) Inpatient mortality of cases who underwent medical management versus intervention (stent or CABG). (b) 1-year all-cause
mortality of patients who underwent medical management versus intervention (stent or CABG).
(a)
Inpatient mortality Inpatient mortality RR 95% CI Stat test 𝑝 value
Number % Yes No
Mean peak troponin
High 8 32 8 13 1.36 0.69–2.67 Chi-square 0.37
Low 17 68 17 44
Ischemic ECG changes
Present 8 32 8 13 1.3669 0.69–2.69 Fisher exact 0.26
Absent 17 68 17 44
Management
Stent/CABG 3 12 8 13 1.36 0.69–2.67 Chi-square 0.37
Medical 22 88 17 44
(b)
1-year all-cause mortality 1-year all-cause mortality RR 95% CI Stat test 𝑝 value
Number % Yes No
Mean peak troponin
High 15 34.88 15 6 1.55 1.06–2.28 Chi-square 0.04
Low 28 65.12 28 33
Ischemic ECG changes
Present 38 88.37 38 34 1.05 0.54–2.03 Fisher exact 0.56
Absent 5 11.63 5 5
Management
Stent/CABG 7 16.28 7 6 1.03 0.59–1.7 Chi-square 0.57
Medical 36 83.72 36 33
abnormalities during the hospitalization [19]. Due to the
retrospective nature of our study, we were not able to follow
the 2D-echocardiograms of our patients during their hospital
stay.
In our study, 67% of patients with acute coronary syn-
drome and acute ischemic stroke did not undergo cardiac
catheterization. There are several factors that may have
influenced this management decision. One is the size of
the stroke. Patients who are deemed at risk of hemorrhagic
conversion do not undergo cardiac catheterization during the
same admission. The procedure may then be scheduled 3–6
months after the stroke. It is also important to note that 29%
of the patients in the study had chronic kidney disease. In
elderly patients, it is not uncommon to encounter patients
and family members refusing cardiac catheterization because
of higher risk of requiring hemodialysis.
Our study also found that older age is associated with
greater likelihood of conservative management (Table 3).
Thismay be because the risks of cardiac catheterization some-
times outweigh the benefits in frail, elderly patients.The level
of troponin also plays a role in deciding themanagement.The
higher it is, the more likely the patient will undergo cardiac
catheterization as this may imply larger cardiac damage
(Table 4). Apart from the age and troponin level, the two
groups (patients whoweremanaged conservatively and those
who underwent cardiac catheterization) did not have any
significant difference in terms of comorbidities (Table 3).
Since the cooccurrence of acute coronary syndrome and
acute ischemic stroke is not common, this study is limited by
its sample size. There is a trend seen in medical management
group and inpatient mortality; however, the limited sample
size may account for why it is not statistically significant.
In conclusion, when clinical characteristics and cardiac
work-up of the medical management group and the inter-
vention group were compared, the only significant difference
was that medical management group had older individuals
(73 versus 67 years), lower mean peak troponin levels (12
versus 49), and lower mean length of stay (12 versus 25 days).
Troponin levels revealed being significantly related to 1-year
all-cause mortality, but not to inpatient mortality. Optimal
medical therapy had similar inpatient and all-cause mortality
compared to PCI and/or CABG.
5. Limitations of the Study
Given the retrospective nature of our study, variables like
severity of stroke, MRI findings for the location of the stroke,
patient frailty, and other related variables were missing in our
patient records and were not included in the study. Sixty-
seven percent of the patients in the study also did not undergo
6 Cardiology Research and Practice
cardiac catheterization. Finally, it is possible that the elevated
troponin levels seen in our patient group were secondary to
catecholamine surge caused by the stroke.
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